1 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Cttq: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody Anlotinib, pd-1 antibody - Advanced Solid Tumor | Phase 2 / Phase 3 | Unknown | Henan Cancer Hospital | 100 | 2019-04-08 | 2019-06-05 |
anlotinib (1) · pembrolizumab (1) · spartalizumab (1)
China (1)
Zibing Wang (1)